The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas
Abstract
CONTEXT: There is no tumor-directed medical therapy available for Cushing's disease. OBJECTIVE: The objective was to determine the in vitro effect of the somatostatin analog pasireotide (SOM230) on cell proliferation in human corticotroph tumors. DESIGN/METHODS: Expression of somatostatin receptors (SSTR 1-5) was determined by quantitative RT-PCR in 13 human corticotroph tumors and by immunohistochemistry (IHC) in 12 of the 13 tumors. SOM230 effects on cell proliferation and ACTH release were evaluated in vitro using primary cultures of six of the 13 human corticotroph adenomas. RESULTS: In our series, we found expression of SSTR subtypes 1, 2, 4, and 5 in human corticotroph tumors by quantitative RT-PCR. All receptor subtypes were detected by IHC, with SSTR subtype 5 having the highest IHC score in 83% (10 of 12) of the cases. Significant suppression of cell proliferation was observed in all tumors cultured (percent suppression range: 10-70%; P = 0.045-0.001). SOM230 inhibited ACTH secretion in five of the six tumors cultured (percent suppression range: 23-56%; P = 0.042-0.001). CONCLUSION: Corticotroph tumors express multiple SSTR subtypes. SOM230 significantly suppressed cell proliferation and ACTH secretion in primary cultures of human corticotroph tumors. These in vitro results support the hypothesis that SOM230 may have a role in the medical therapy of corticotroph tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Diagnosis and Management of Cushing’s Syndrome: Results of an Italian Multicentre Study 1
Invitti, C., Giraldi, F. P., De Martin, M., & Cavagnini, F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5465 · Cited by 336
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationTreatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Self-citationA 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Pasireotide (SOM230): Development, mechanism of action and potential applications
Schmid, H. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.09.006 · Cited by 290
Boscaro, M., Ludlam, W. H., Atkinson, B., Glusman, J. E., Petersenn, S., Reincke, M., Snyder, P., Tabarin, A., Biller, B. M. K., Findling, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1008 · Cited by 279
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
Treatment of Cushing disease: overview and recent findings
Giustina, A. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s12952 · Cited by 66
“…of SS analogs in human corticotroph adenoma tissues; a superior ACTH inhibition by pasireotide as compared with octreotide 55 and a dissociation in some adenomas between the antisecretory and antiproliferative effects of pasireotide 56 were reported similar to what is observed in acromegaly.”
Nishioka, H., & Yamada, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111951 · Cited by 65
Tani, Y., Sugiyama, T., Izumiyama, H., Yoshimoto, T., Yamada, S., & Hirata, Y. (2011) · Endocrine Journal · doi:10.1507/endocrj.k10e-389 · Cited by 25
Metadata
- Authors
- Batista, D. L., Zhang, X., Gejman, R., Ansell, P. J., Zhou, Y., Johnson, S. A., Swearingen, B., Hedley-Whyte, E. T., Stratakis, C. A., & Klibanski, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-11
- Volume
- 91
- Issue
- 11
- Pages
- 4482-4488
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2057835402
- Cited by
- 201
- References
- 2
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.